Related Experiment Video
Updated: Feb 4, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study
Nergiz Erkut1, Osman Akidan2, Derya Selim Batur3
1Department of Hematology, School of Medicine, Karadeniz Technical University, Trabzon, Turkeydrnusta@hotmail.com.
Insights
This study compared two adult acute lymphoblastic leukemia (ALL) chemotherapy regimens, Hyper-CVAD and PETHEMA ALL-93. While both showed similar survival outcomes, Hyper-CVAD was better tolerated with fewer toxicities.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Adult acute lymphoblastic leukemia (ALL) has lower cure rates compared to pediatric ALL.
- Current treatments include Hyper-CVAD and PETHEMA ALL-93, but direct comparisons are lacking.
Purpose of the Study:
- To compare the efficacy and safety of Hyper-CVAD and PETHEMA ALL-93 regimens in adult ALL patients.
- To evaluate complete response, overall survival, and disease-free survival rates.
- To assess treatment-related toxicities between the two regimens.
Main Methods:
- Retrospective single-center study of 51 adult ALL patients.
- Patients received either Hyper-CVAD (38 patients) or PETHEMA ALL-93 (13 patients).
- Data collected on treatment response, survival, and adverse events.
Main Results:
- Complete response rates were 90% for Hyper-CVAD and 100% for PETHEMA ALL-93.
- Median overall survival and disease-free survival were comparable between regimens (approx. 18 months OS, 13 months DFS).
- PETHEMA ALL-93 was associated with higher rates of hepatotoxicity, hypofibrinogenemia, aspergillus infection, and skin rash compared to Hyper-CVAD.
Conclusions:
- Hyper-CVAD and PETHEMA ALL-93 demonstrate similar survival outcomes in adult ALL.
- Hyper-CVAD exhibited a better safety profile with fewer adverse events.
- Patient age and comorbidities are crucial factors in selecting the optimal chemotherapy regimen.
Background:
Although cure rates in pediatric acute lymphoblastic leukemia (ALL) are quite high with combined chemotherapy regimens, complete response (CR) and long-term survival rates in adults are 80-90 and 30-40%, respectively. Currently, combined chemotherapy regimens, such as Hyper-CVAD and PETHEMA, are used in patients with adult ALL. However, there has been no study comparing the results of Hyper-CVAD and PETHEMA ALL-93.
Methods:
In this retrospective single-center study, we evaluated the results of Hyper-CVAD and PETHEMA ALL-93 in 51 ALL patients treated between September 2008 and March 2017 at the Department of Hematology, Faculty of Medicine, Karadeniz Technical University.
Results:
Thirty-eight patients were treated with Hyper-CVAD and 13 with PETHEMA ALL-93. CR was obtained in 90 and 100% of patients, respectively. Survival estimates were comparable between Hyper-CVAD and PE-THEMA ALL-93, with a median overall survival (OS) and a median disease-free survival (DFS) of 17.5 and 12.1 months, respectively, for Hyper-CVAD and of 18.6 and 12.9 months, respectively, for PETHEMA ALL-93. The 2-year OS rates for Hyper-CVAD and PETHEMA ALL-93 were 30 and 40%, respectively, and the 2-year DFS rates were 28 and 44%, respectively. PETHEMA ALL-93 resulted in more hepatotoxicity, hypofibrinogenemia, aspergillus infection, and skin rash than Hyper-CVAD.
Conclusions:
Although Hyper-CVAD and PE-THEMA ALL-93 showed similar effects, Hyper-CVAD was tolerated better. Age and comorbidities should be taken into account before a chemotherapy regimen is determined for patients with ALL.
Related Concept Videos
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...
Acute Pyelonephritis II: Diagnostic Studies and Management
Center of Mass
The knowledge of the center of mass can also help us to describe and predict the motion of objects. For example, when a ball is thrown...

